CLASSIFICATION, PREVALENCE AND TREATMENT OF HEPACVIRIUS C

Authors

  • HAU HASSAN Institute of Molecular Biology and Biotechnology, The University of Lahore, Pakistan Author
  • A RIASAT School of Allied Health and Social Care, Anglia Ruskin University (ARU), East Anglia, United Kingdom Author
  • T ZIA Cell development and Microbiology, Department of biological Sciences, Ohio University, Athens OH, United States Author
  • S ISHAQ Department of Biomedical Engineering (Medicine), Guangdong Provincial Key Laboratory of System Biology and Synthetics Biology for Urogenital Tumors, Shenzhen University (SZU), Guangdong, China Author
  • A ULLAH Institute of Translational Pathology, University Hospital Cologne, Cologne, Germany Author

DOI:

https://doi.org/10.64013/jpbab.v2024i1.33

Keywords:

HCV, drugs, Ribavirin, interferon, antivirals, Hepacivirus

Abstract

Hepacivirus C has been remembered for the Flaviviridae family. It encompasses positive sense RNA infection and an individual from the Hepacivirus species. It's the overall issue and its predominance differs throughout the world while the greater part was in the USA however, now Egypt is the most influenced one. Its genotype varies because of the higher rate of recombination in the RNA genome. HCV significant transmission occurs due to blood transfusion. It can cause exhaustion, jaundice, anorexia, and numerous different diseases. It likewise impacts the liver if it’s in a persistent structure. Genotypes and subtypes are 8 and numerous (to be exact right around 126) individually. Genotype 1 has the most significant rate around the planet which influences around 40-80% of the population. USA has the most significant level of 1a and 1b, while in different nations genotype 1a isn't so normal. Pakistan has the most elevated level of HCV genotype 3a. Medicines have been built up that incorporate DAA (direct-acting antivirals), IFN-α (interferon alpha) Ribavirin, etc. A profoundly viable treatment is DAA. It may be utilized for the treatment of all age patients and the most elevated adequacy rate has been seen in youngsters because of DAA treatment. Interferon is given in a mix with other drugs. In recent years, practically half of the ongoing HCV-tainted patients have been restored with treatment other than DAA which includes ribavirin and interferon.

Downloads

Download data is not yet available.

References

Aghemo, A., and Colombo, M. J. G. (2014). Treatment of patients with dual hepatitis B and C: a step in the right direction. 63, 380-381. DOI: https://doi.org/10.1136/gutjnl-2013-305115

Ahmad, I., Khan, S. B., ur Rehman, H., Khan, M. H., and Anwar, S. (2006). Frequency of Hepatitis B and Hepatitis C among cataract patients.

Alric, L., Fort, M., Izopet, J., Vinel, J., Charlet, J., Selves, J., Puel, J., Pascal, J., Duffaut, M., and Abbal, M. J. G. (1997). Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. 113, 1675-1681. DOI: https://doi.org/10.1053/gast.1997.v113.pm9352872

Altekruse, S. F., Henley, S. J., Cucinelli, J. E., and McGlynn, K. A. J. T. A. j. o. g. (2014). Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. 109, 542. DOI: https://doi.org/10.1038/ajg.2014.11

Alter, M. J. J. W. j. o. g. W. (2007). Epidemiology of hepatitis C virus infection. 13, 2436. DOI: https://doi.org/10.3748/wjg.v13.i17.2436

Amin, F., Hassan, N., Bashir, K., Khan, A., Bibi, H., Irshad, M., Khan, S., Nawaz, K., and Ullah, Z. (2023). Antimicrobial susceptibility profile of various bacteria isolated from respiratory tract infection. Bulletin of Biological and Allied Sciences Research 2023, 48-48. DOI: https://doi.org/10.54112/bbasr.v2023i1.48

Amjad, N., Rehman, M., Khalid, M., and Amjad, I. (2018). Construction of the infectious molecule of beta satellite associated with ageratum yellow vein disease of ageratum conyzoides. Bulletin of Biological and Allied Sciences Research 2018, 13-13. DOI: https://doi.org/10.54112/bbasr.v2018i1.13

Andre, P., Komurian-Pradel, F., Deforges, S., Perret, M., Berland, J., Sodoyer, M., Pol, S., Brechot, C., Paranhos-Baccala, G., and Lotteau, V. J. J. o. v. (2002). Characterization of low-and very-low-density hepatitis C virus RNA-containing particles. 76, 6919-6928. DOI: https://doi.org/10.1128/JVI.76.14.6919-6928.2002

Awan, S. J., Fatima, Z., Kamran, S., Khan, A. S., Fatima, T., Imran, S., Shabbir, M., and Nadeem, S. I. (2024). Guar gum in therapeutics: a succinct exploration. Bulletin of Biological and Allied Sciences Research 2024, 60. DOI: https://doi.org/10.54112/bbasr.v2024i1.60

Baid, S., Tolkoff‐Rubin, N., Saidman, S., Chung, R., Williams, W. W., Auchincloss, H., Colvin, R. B., Delmonico, F. L., Cosimi, A. B., and Pascual, M. J. A. J. o. T. (2003). Acute humoral rejection in hepatitis C‐infected renal transplant recipients receiving antiviral therapy. 3, 74-78. DOI: https://doi.org/10.1034/j.1600-6143.2003.30113.x

Bartenschlager, R., Lohmann, V., and Penin, F. J. N. R. M. (2013). The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. 11, 482-496. DOI: https://doi.org/10.1038/nrmicro3046

Bostan, N., and Mahmood, T. J. C. r. i. m. (2010). An overview about hepatitis C: a devastating virus. 36, 91-133. DOI: https://doi.org/10.3109/10408410903357455

Boulant, S., Vanbelle, C., Ebel, C., Penin, F., and Lavergne, J.-P. J. J. o. v. (2005). Hepatitis C virus core protein is a dimeric alpha-helical protein exhibiting membrane protein features. 79, 11353-11365. DOI: https://doi.org/10.1128/JVI.79.17.11353-11365.2005

Brookman-May, S. D., Rodriguez-Faba, O., Langenhuijsen, J. F., Akdogan, B., Linares, E., Minervini, A., Klatte, T., Volpe, A., Brausi, M., and Marszalek, M. J. A. i. M. O. R. (2017). Challenges, hurdles and possible approaches to improve cancer care in developing countries–A short breakdown of the status quo and future perspective. 3, 204-212. DOI: https://doi.org/10.18282/amor.v3.i5.221

Cacoub, P., Poynard, T., Ghillani, P., Charlotte, F., Olivi, M., Charles Piette, J., Opolon, P. J. A., and Rheumatology, R. O. J. o. t. A. C. o. (1999). Extrahepatic manifestations of chronic hepatitis C. 42, 2204-2212. DOI: https://doi.org/10.1002/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D

Calattini, S., Fusil, F., Mancip, J., Thi, V. L. D., Granier, C., Gadot, N., Scoazec, J.-Y., Zeisel, M. B., Baumert, T. F., and Lavillette, D. J. J. o. B. C. (2015). Functional and biochemical characterization of hepatitis C virus (HCV) particles produced in a humanized liver mouse model. 290, 23173-23187. DOI: https://doi.org/10.1074/jbc.M115.662999

Cancer, I. A. f. R. o. (2012). GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012.

Choo, Q.-L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., and Houghton, M. J. S. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. 244, 359-362. DOI: https://doi.org/10.1126/science.2523562

Colombo, M., Choo, Q., Del Ninno, E., Dioguardi, N., Kuo, G., Donato, M., Tommasini, M., and Houghton, M. J. T. L. (1989). Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. 334, 1006-1008. DOI: https://doi.org/10.1016/S0140-6736(89)91016-7

Cooke, G., Lemoine, M., Thursz, M., Gore, C., Swan, T., Kamarulzaman, A., DuCros, P., and Ford, N. J. J. o. v. h. (2013). Viral hepatitis and the Global Burden of Disease: a need to regroup. 20, 600-601. DOI: https://doi.org/10.1111/jvh.12123

Davis, G. L., Wong, J. B., McHutchison, J. G., Manns, M. P., Harvey, J., and Albrecht, J. J. H. (2003). Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. 38, 645-652. DOI: https://doi.org/10.1053/jhep.2003.50364

Dazert, E., Neumann-Haefelin, C., Bressanelli, S., Fitzmaurice, K., Kort, J., Timm, J., McKiernan, S., Kelleher, D., Gruener, N., and Tavis, J. E. J. T. J. o. c. i. (2009). Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27–restricted human immune response. 119, 376-386. DOI: https://doi.org/10.1172/JCI36587

De Francesco, R., Tomei, L., Altamura, S., Summa, V., and Migliaccio, G. J. A. r. (2003). Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. 58, 1-16. DOI: https://doi.org/10.1016/S0166-3542(03)00028-7

Dustin, L. B., Bartolini, B., Capobianchi, M. R., Pistello, M. J. C. m., and infection (2016). Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. 22, 826-832. DOI: https://doi.org/10.1016/j.cmi.2016.08.025

Fan, W., Zhu, W., Wei, L., Wang, Q., Yin, L., Du, S., and Zhuang, H. J. J. o. g. (2005). Nonstructural 5A gene variability of hepatitis C virus (HCV) during a 10-year follow up. 40, 43-51. DOI: https://doi.org/10.1007/s00535-004-1446-2

Feinstone, S. M., Kapikian, A. Z., Purcell, R. H., Alter, H. J., and Holland, P. V. J. N. E. J. o. M. (1975). Transfusion-associated hepatitis not due to viral hepatitis type A or B. 292, 767-770. DOI: https://doi.org/10.1056/NEJM197504102921502

Finkelmeier, F., Dultz, G., Peiffer, K.-H., Kronenberger, B., Krauss, F., Zeuzem, S., Sarrazin, C., Vermehren, J., and Waidmann, O. J. L. C. (2018). Risk of de novo hepatocellular carcinoma after HCV treatment with direct-acting antivirals. 7, 190-204. DOI: https://doi.org/10.1159/000486812

Fusaro, A., Monne, I., Salviato, A., Valastro, V., Schivo, A., Amarin, N. M., Gonzalez, C., Ismail, M. M., Al-Ankari, A.-R., and Al-Blowi, M. H. J. J. o. v. (2011). Phylogeography and evolutionary history of reassortant H9N2 viruses with potential human health implications. 85, 8413-8421. DOI: https://doi.org/10.1128/JVI.00219-11

Geddawy, A., Ibrahim, Y. F., Elbahie, N. M., and Ibrahim, M. A. J. J. o. t. i. m. (2017). Direct acting anti-hepatitis C virus drugs: clinical pharmacology and future direction. 5, 8-17. DOI: https://doi.org/10.1515/jtim-2017-0007

Gerresheim, G. K., Dünnes, N., Nieder-Röhrmann, A., Shalamova, L. A., Fricke, M., Hofacker, I., Zu Siederdissen, C. H., Marz, M., Niepmann, M. J. C., and sciences, m. l. (2017). microRNA-122 target sites in the hepatitis C virus RNA NS5B coding region and 3′ untranslated region: function in replication and influence of RNA secondary structure. 74, 747-760. DOI: https://doi.org/10.1007/s00018-016-2377-9

Gohar, M., Rehman, I., Ahmad, J., Ahmad, F., Bashir, K., Ikram, S., Hassan, N., Khan, M., and Ullah, A. (2023). Prevalence of hepatitis b virus and genotypes in the region of khyber pakhtunkhwa Pakistan. Bulletin of Biological and Allied Sciences Research 2023, 53-53. DOI: https://doi.org/10.54112/bbasr.v2023i1.53

Grakoui, A., McCourt, D., Wychowski, C., Feinstone, S., and Rice, C. J. J. o. v. (1993a). Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. 67, 2832-2843. DOI: https://doi.org/10.1128/jvi.67.5.2832-2843.1993

Grakoui, A., McCourt, D. W., Wychowski, C., Feinstone, S. M., and Rice, C. M. J. P. o. t. N. A. o. S. (1993b). A second hepatitis C virus-encoded proteinase. 90, 10583-10587. DOI: https://doi.org/10.1073/pnas.90.22.10583

Greten, T., Papendorf, F., Bleck, J., Kirchhoff, T., Wohlberedt, T., Kubicka, S., Klempnauer, J., Galanski, M., and Manns, M. J. B. j. o. c. (2005). Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. 92, 1862-1868. DOI: https://doi.org/10.1038/sj.bjc.6602590

Griffin, S. D., Beales, L. P., Clarke, D. S., Worsfold, O., Evans, S. D., Jaeger, J., Harris, M. P., and Rowlands, D. J. J. F. l. (2003). The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. 535, 34-38. DOI: https://doi.org/10.1016/S0014-5793(02)03851-6

Guerra, J., Garenne, M., Mohamed, M., and Fontanet, A. J. J. o. v. h. (2012). HCV burden of infection in Egypt: results from a nationwide survey. 19, 560-567. DOI: https://doi.org/10.1111/j.1365-2893.2011.01576.x

Gutelius, B., Perz, J. F., Parker, M. M., Hallack, R., Stricof, R., Clement, E. J., Lin, Y., Xia, G.-L., Punsalang, A., and Eramo, A. J. G. (2010). Multiple clusters of hepatitis virus infections associated with anesthesia for outpatient endoscopy procedures. 139, 163-170. DOI: https://doi.org/10.1053/j.gastro.2010.03.053

Hagström, H. J. C. h. r. (2017). Alcohol consumption in concomitant liver disease: how much is too much? 16, 152-157. DOI: https://doi.org/10.1007/s11901-017-0343-0

Hajarizadeh, B., Grebely, J., Dore, G. J. J. N. r. G., and hepatology (2013). Epidemiology and natural history of HCV infection. 10, 553. DOI: https://doi.org/10.1038/nrgastro.2013.107

Hassan, N., Amin, F., Bashir, K., Irshad, M., Jamil, S., Munawar, N., Haqqani, H., Shabir, H., and Khan, M. (2023). Antiviral response of drugs used against hbv patients of Khyber Pakhtunkhwa, Pakistan. Bulletin of Biological and Allied Sciences Research 2023, 49-49. DOI: https://doi.org/10.54112/bbasr.v2023i1.49

Holz, L., and Rehermann, B. J. A. r. (2015). T cell responses in hepatitis C virus infection: historical overview and goals for future research. 114, 96-105. DOI: https://doi.org/10.1016/j.antiviral.2014.11.009

Horner, S. M., and Gale, M. J. N. m. (2013). Regulation of hepatic innate immunity by hepatitis C virus. 19, 879-888. DOI: https://doi.org/10.1038/nm.3253

Huang, H., Sun, F., Owen, D. M., Li, W., Chen, Y., Gale, M., and Ye, J. J. P. o. t. N. A. o. S. (2007). Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. 104, 5848-5853. DOI: https://doi.org/10.1073/pnas.0700760104

Jimenez, A. P., Eldin, N. S., Rimlinger, F., El-Daly, M., El-Hariri, H., El-Hoseiny, M., Mohsen, A., Mostafa, A., Delarocque-Astagneau, E., and Abdel-Hamid, M. J. G. (2010). HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. 59, 1554-1560. DOI: https://doi.org/10.1136/gut.2009.194266

Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., and Sarnow, P. J. s. (2005). Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. 309, 1577-1581. DOI: https://doi.org/10.1126/science.1113329

Karoney, M. J., and Siika, A. M. J. P. A. m. j. (2013). Hepatitis C virus (HCV) infection in Africa: a review. 14. DOI: https://doi.org/10.11604/pamj.2013.14.44.2199

Kato, N. J. M., and genomics, c. (2000). Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation. 5, 129-151. DOI: https://doi.org/10.1089/mcg.2000.5.129

Keating, G. M., and Vaidya, A. J. D. (2014). Sofosbuvir: first global approval. 74, 273-282. DOI: https://doi.org/10.1007/s40265-014-0179-7

Kenny-Walsh, E. J. N. E. J. o. M. (1999). Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. 340, 1228-1233. DOI: https://doi.org/10.1056/NEJM199904223401602

Khan, N., Akmal, M., Hayat, M., Umar, M., Ullah, A., Ahmed, I., Rahim, K., Ali, S., Bahadar, S., and Saleha, S. J. H. m. (2014). Geographic distribution of hepatitis C virus genotypes in pakistan. 14. DOI: https://doi.org/10.5812/hepatmon.20299

Kokudo, N., Takemura, N., Hasegawa, K., Takayama, T., Kubo, S., Shimada, M., Nagano, H., Hatano, E., Izumi, N., and Kaneko, S. J. H. R. (2019). Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update. 49, 1109-1113. DOI: https://doi.org/10.1111/hepr.13411

Kramer, J. R., Kowalkowski, M. A., Duan, Z., and Chiao, E. Y. J. J. J. o. A. I. D. S. (2015). The effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection. 68, 456-462. DOI: https://doi.org/10.1097/QAI.0000000000000494

Krekulova, L., Řehák, V., and Riley, L. J. F. m. (2006). Structure and functions of hepatitis C virus proteins: 15 years after. 51, 665-680. DOI: https://doi.org/10.1007/BF02931636

Kruse, R. L., Kramer, J. R., Tyson, G. L., Duan, Z., Chen, L., El‐Serag, H. B., and Kanwal, F. J. H. (2014). Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus‐infected patients. 60, 1871-1878. DOI: https://doi.org/10.1002/hep.27337

Lamoury, F. M., Bajis, S., Hajarizadeh, B., Marshall, A. D., Martinello, M., Ivanova, E., Catlett, B., Mowat, Y., Marks, P., and Amin, J. J. T. J. o. i. d. (2018). Evaluation of the Xpert HCV viral load finger-stick point-of-care assay. 217, 1889-1896. DOI: https://doi.org/10.1093/infdis/jiy114

Laperche, S., and Transfusion, F. A. G. f. R. i. B. T. J. (2013). Multinational assessment of blood‐borne virus testing and transfusion safety on the African continent. 53, 816-826. DOI: https://doi.org/10.1111/j.1537-2995.2012.03797.x

Lavanchy, D. J. C. M., and Infection (2011). Evolving epidemiology of hepatitis C virus. 17, 107-115. DOI: https://doi.org/10.1111/j.1469-0691.2010.03432.x

Lok, A. S., Seeff, L. B., Morgan, T. R., Di Bisceglie, A. M., Sterling, R. K., Curto, T. M., Everson, G. T., Lindsay, K. L., Lee, W. M., and Bonkovsky, H. L. J. G. (2009). Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. 136, 138-148. DOI: https://doi.org/10.1053/j.gastro.2008.09.014

Lundin, M., Lindström, H., Grönwall, C., and Persson, M. A. J. J. o. g. v. (2006). Dual topology of the processed hepatitis C virus protein NS4B is influenced by the NS5A protein. 87, 3263-3272. DOI: https://doi.org/10.1099/vir.0.82211-0

Maggi, F., Focosi, D., and Pistello, M. J. C. d. t. (2017). How Current Direct-Acting Antiviral and Novel Cell Culture Systems for HCV are Shaping Therapy and Molecular Diagnosis of Chronic HCV Infection? 18, 811-825. DOI: https://doi.org/10.2174/1389450116666150806123119

Magiorkinis, G., Magiorkinis, E., Paraskevis, D., Ho, S. Y., Shapiro, B., Pybus, O. G., Allain, J.-P., and Hatzakis, A. J. P. M. (2009). The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. 6, e1000198. DOI: https://doi.org/10.1371/journal.pmed.1000198

Mahale, P., Torres, H. A., Kramer, J. R., Hwang, L. Y., Li, R., Brown, E. L., and Engels, E. A. J. C. (2017). Hepatitis C virus infection and the risk of cancer among elderly US adults: a registry‐based case‐control study. 123, 1202-1211. DOI: https://doi.org/10.1002/cncr.30559

Mancebo, A., González–Diéguez, M. L., Cadahía, V., Varela, M., Pérez, R., Navascués, C. A., Sotorríos, N. G., Martínez, M., Rodrigo, L., Rodríguez, M. J. C. g., and hepatology (2013). Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. 11, 95-101. DOI: https://doi.org/10.1016/j.cgh.2012.09.007

Marcellin, P. J. L. I. (2009). Hepatitis B and hepatitis C in 2009. 29, 1-8. DOI: https://doi.org/10.1111/j.1478-3231.2008.01947.x

Margraf, R. L., Erali, M., Liew, M., and Wittwer, C. T. J. J. o. c. m. (2004). Genotyping hepatitis C virus by heteroduplex mobility analysis using temperature gradient capillary electrophoresis. 42, 4545-4551. DOI: https://doi.org/10.1128/JCM.42.10.4545-4551.2004

McLauchlan, J. J. J. o. v. h. (2000). Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. 7, 2-14. DOI: https://doi.org/10.1046/j.1365-2893.2000.00201.x

Murphy, D. G., Willems, B., Deschênes, M., Hilzenrat, N., Mousseau, R., and Sabbah, S. J. J. o. c. m. (2007). Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′ untranslated region sequences. 45, 1102-1112. DOI: https://doi.org/10.1128/JCM.02366-06

Nouroz, F., Shaheen, S., Mujtaba, G., and Noreen, S. J. E. J. o. M. H. G. (2015). An overview on hepatitis C virus genotypes and its control. 16, 291-298. DOI: https://doi.org/10.1016/j.ejmhg.2015.05.003

Obaid, A., Ahmad, J., Naz, A., Awan, F. M., Paracha, R. Z., Tareen, S. H. K., Anjum, S., Raza, A., Baumbach, J., and Ali, A. J. I. B. (2015). Modeling and analysis of innate immune responses induced by the host cells against hepatitis C virus infection. 7, 544-559. DOI: https://doi.org/10.1039/c4ib00285g

Okuda, M., Li, K., Beard, M. R., Showalter, L. A., Scholle, F., Lemon, S. M., and Weinman, S. A. J. G. (2002). Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. 122, 366-375. DOI: https://doi.org/10.1053/gast.2002.30983

Patel, P. R., Larson, A. K., Castel, A. D., Ganova-Raeva, L. M., Myers, R. A., Roup, B. J., Farrell, K. P., Edwards, L., Nainan, O., and Krick, J. P. J. J. (2006). Hepatitis C virus infections from a contaminated radiopharmaceutical used in myocardial perfusion studies. 296, 2005-2011. DOI: https://doi.org/10.1001/jama.296.16.2005

Paul, D., Madan, V., Bartenschlager, R. J. C. h., and microbe (2014). Hepatitis C virus RNA replication and assembly: living on the fat of the land. 16, 569-579. DOI: https://doi.org/10.1016/j.chom.2014.10.008

Petruzziello, A., Marigliano, S., Loquercio, G., Cozzolino, A., and Cacciapuoti, C. J. W. j. o. g. (2016). Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. 22, 7824. DOI: https://doi.org/10.3748/wjg.v22.i34.7824

Pietschmann, T., Kaul, A., Koutsoudakis, G., Shavinskaya, A., Kallis, S., Steinmann, E., Abid, K., Negro, F., Dreux, M., and Cosset, F.-L. J. P. o. t. N. A. o. S. (2006). Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. 103, 7408-7413. DOI: https://doi.org/10.1073/pnas.0504877103

Prati, D. J. J. o. h. (2006). Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. 45, 607-616. DOI: https://doi.org/10.1016/j.jhep.2006.07.003

Puchades Renau, L., and Berenguer, M. J. H. I. (2018). Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies. 22, S8-S21. DOI: https://doi.org/10.1111/hdi.12647

Quan, V. M., Go, V. F., Nam, L. V., Bergenstrom, A., Thuoc, N. P., Zenilman, J., Latkin, C., and Celentano, D. D. J. A. c. (2009). Risks for HIV, HBV, and HCV infections among male injection drug users in northern Vietnam: a case–control study. 21, 7-16. DOI: https://doi.org/10.1080/09540120802017610

Raja, N. S., Janjua, K. A. J. J. o. M., Immunology,, and Infection (2008). Epidemiology of hepatitis C virus infection in Pakistan. 41, 4-8.

Rauf, A., Nadeem, M. S., Ali, A., Iqbal, M., Mustafa, M., Muzammal Latif, M., Latif, M. Z., Ahmed, N., and Shakoori, A. R. J. T. E. J. o. P. H. (2011). Prevalence of hepatitis B and C in internally displaced persons of war against terrorism in Swat, Pakistan. 21, 638-642. DOI: https://doi.org/10.1093/eurpub/ckq084

Report, W. H. O. J. S. (2011). Global database on blood safety. 2011, 3-4.

Roberts, E. A., and Yeung, L. J. H. (2002). Maternal‐infant transmission of hepatitis C virus infection. 36, S106-S113. DOI: https://doi.org/10.1053/jhep.2002.36792

Rosa, D., Campagnoli, S., Moretto, C., Guenzi, E., Cousens, L., Chin, M., Dong, C., Weiner, A. J., Lau, J., and Choo, Q.-L. J. P. o. t. N. A. o. S. (1996). A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. 93, 1759-1763. DOI: https://doi.org/10.1073/pnas.93.5.1759

Santolini, E., Pacini, L., Fipaldini, C., Migliaccio, G., and Monica, N. J. J. o. v. (1995). The NS2 protein of hepatitis C virus is a transmembrane polypeptide. 69, 7461-7471. DOI: https://doi.org/10.1128/jvi.69.12.7461-7471.1995

Scheel, T. K., Gottwein, J. M., Jensen, T. B., Prentoe, J. C., Hoegh, A. M., Alter, H. J., Eugen-Olsen, J., and Bukh, J. J. P. o. t. N. A. o. S. (2008). Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. 105, 997-1002. DOI: https://doi.org/10.1073/pnas.0711044105

Scheel, T. K., and Rice, C. M. J. N. m. (2013). Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. 19, 837-849. DOI: https://doi.org/10.1038/nm.3248

Schoggins, J. W., and Rice, C. M. J. H. C. V. F. M. V. t. A. T. (2013). Innate immune responses to hepatitis C virus. 219-242. DOI: https://doi.org/10.1007/978-3-642-27340-7_9

Schulze-Krebs, A., Preimel, D., Popov, Y., Bartenschlager, R., Lohmann, V., Pinzani, M., and Schuppan, D. J. G. (2005). Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. 129, 246-258. DOI: https://doi.org/10.1053/j.gastro.2005.03.089

Sheahan, T., Imanaka, N., Marukian, S., Dorner, M., Liu, P., Ploss, A., Rice, C. M. J. C. h., and microbe (2014). Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. 15, 190-202. DOI: https://doi.org/10.1016/j.chom.2014.01.007

Sheema, Bashir, K., Fiaz, S., Khan, A. W., Haqqani, S., Bibi, A., Nawaz, K., Khan, M. A., and Ullah, A. (2024). Molecular identification of hcv genotypes among injecting drug users having HCV and HIV co-infection. Bulletin of Biological and Allied Sciences Research 2024, 71. DOI: https://doi.org/10.54112/bbasr.v2024i1.71

Shekhar, S. (2018). Hepatitis C Virus Infection in the Indian Sub-Continent. In "Hepatitis C in Developing Countries", pp. 83-95. Elsevier. DOI: https://doi.org/10.1016/B978-0-12-803233-6.00008-4

Shimakami, T., Yamane, D., Jangra, R. K., Kempf, B. J., Spaniel, C., Barton, D. J., and Lemon, S. M. J. P. o. t. N. A. o. S. (2012). Stabilization of hepatitis C virus RNA by an Ago2–miR-122 complex. 109, 941-946. DOI: https://doi.org/10.1073/pnas.1112263109

Sievert, W., Altraif, I., Razavi, H. A., Abdo, A., Ahmed, E. A., AlOmair, A., Amarapurkar, D., Chen, C. H., Dou, X., and El Khayat, H. J. L. i. (2011). A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. 31, 61-80. DOI: https://doi.org/10.1111/j.1478-3231.2011.02540.x

Simmonds, P. J. J. o. G. V. (2004). Genetic diversity and evolution of hepatitis C virus–15 years on. 85, 3173-3188. DOI: https://doi.org/10.1099/vir.0.80401-0

Smith, D. B., Bukh, J., Kuiken, C., Muerhoff, A. S., Rice, C. M., Stapleton, J. T., and Simmonds, P. J. H. (2014). Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. 59, 318-327. DOI: https://doi.org/10.1002/hep.26744

Stanaway, J. D., Flaxman, A. D., Naghavi, M., Fitzmaurice, C., Vos, T., Abubakar, I., Abu-Raddad, L. J., Assadi, R., Bhala, N., and Cowie, B. J. T. L. (2016). The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. 388, 1081-1088. DOI: https://doi.org/10.1016/S0140-6736(16)30579-7

Steinmann, E., Penin, F., Kallis, S., Patel, A. H., Bartenschlager, R., and Pietschmann, T. J. P. P. (2007). Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. 3, e103. DOI: https://doi.org/10.1371/journal.ppat.0030103

Strader, D. B., and Seeff, L. B. J. C. L. D. (2012). A brief history of the treatment of viral hepatitis C. 1, 6-11. DOI: https://doi.org/10.1002/cld.1

Tagny, C. T., Mbanya, D., Tapko, J. B., and Lefrère, J. J. J. T. (2008). Blood safety in Sub‐Saharan Africa: a multi‐factorial problem. 48, 1256-1261. DOI: https://doi.org/10.1111/j.1537-2995.2008.01697.x

Te, H. S., Randall, G., Jensen, D. M. J. G., and hepatology (2007). Mechanism of action of ribavirin in the treatment of chronic hepatitis C. 3, 218.

Terrault, N. A. J. H. (2002). Sexual activity as a risk factor for hepatitis C. 36, S99-S105. DOI: https://doi.org/10.1053/jhep.2002.36797

Thein, H. H., Yi, Q., Dore, G. J., and Krahn, M. D. J. H. (2008). Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infection: a meta‐analysis and meta‐regression. 48, 418-431. DOI: https://doi.org/10.1002/hep.22375

Thompson, N. D., Perz, J. F., Moorman, A. C., and Holmberg, S. D. J. A. o. I. M. (2009). Nonhospital health care–associated hepatitis B and C virus transmission: United States, 1998–2008. 150, 33-39. DOI: https://doi.org/10.7326/0003-4819-150-1-200901060-00007

Tomasetti, C., Li, L., and Vogelstein, B. J. S. (2017). Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. 355, 1330-1334. DOI: https://doi.org/10.1126/science.aaf9011

Tong, M. J., El-Farra, N. S., Reikes, A. R., and Co, R. L. J. N. E. J. o. M. (1995). Clinical outcomes after transfusion-associated hepatitis C. 332, 1463-1466. DOI: https://doi.org/10.1056/NEJM199506013322202

Turner, K. M., Hutchinson, S., Vickerman, P., Hope, V., Craine, N., Palmateer, N., May, M., Taylor, A., De Angelis, D., and Cameron, S. J. A. (2011). The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. 106, 1978-1988. DOI: https://doi.org/10.1111/j.1360-0443.2011.03515.x

Ullah, I., Ullah, A., Rehman, S., Ullah, S., Ullah, H., Haqqni, S., Amir, M., Gul, F., and Bashir, K. (2023). Prevalence and risk factors of helicobacter pylori infection among individuals with tobacco consumption habits in district Peshawar: a cross-sectional study. Bulletin of Biological and Allied Sciences Research 2023, 42-42. DOI: https://doi.org/10.54112/bbasr.v2023i1.42

van de Laar, T. J., Matthews, G. V., Prins, M., and Danta, M. J. A. (2010). Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. 24, 1799-1812. DOI: https://doi.org/10.1097/QAD.0b013e32833c11a5

Velati, C., Romanò, L., Baruffi, L., Pappalettera, M., Carreri, V., and Zanetti, A. R. J. T. (2002). Residual risk of transfusion‐transmitted HCV and HIV infections by antibody‐screened blood in Italy. 42, 989-993. DOI: https://doi.org/10.1046/j.1537-2995.2002.00173.x

Vescovo, T., Refolo, G., Vitagliano, G., Fimia, G. M., Piacentini, M. J. C. M., and Infection (2016). Molecular mechanisms of hepatitis C virus–induced hepatocellular carcinoma. 22, 853-861. DOI: https://doi.org/10.1016/j.cmi.2016.07.019

Wang, H., Naghavi, M., Allen, C., Barber, R., Carter, A., Casey, D., Charlson, F., Chen, A., Coates, M., and Coggeshall, M. J. T. L. (2016). Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â 2015: a systematic analysis for the Global Burden of Disease Study 2015. 388, 1459-1544.

Wieland, S., Makowska, Z., Campana, B., Calabrese, D., Dill, M. T., Chung, J., Chisari, F. V., and Heim, M. H. J. H. (2014). Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. 59, 2121-2130. DOI: https://doi.org/10.1002/hep.26770

Wölk, B., Sansonno, D., Kräusslich, H.-G., Dammacco, F., Rice, C. M., Blum, H. E., and Moradpour, D. J. J. o. v. (2000). Subcellular localization, stability, andtrans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. 74, 2293-2304. DOI: https://doi.org/10.1128/JVI.74.5.2293-2304.2000

Yamaga, A. K., and Ou, J.-h. J. J. o. B. C. (2002). Membrane topology of the hepatitis C virus NS2 protein. 277, 33228-33234. DOI: https://doi.org/10.1074/jbc.M202304200

Yang, J. D., and Roberts, L. R. J. I. D. C. (2010). Epidemiology and management of hepatocellular carcinoma. 24, 899-919. DOI: https://doi.org/10.1016/j.idc.2010.07.004

Zeisel, M. B., Felmlee, D. J., and Baumert, T. F. J. H. C. V. F. M. V. t. A. T. (2013). Hepatitis C virus entry. 87-112. DOI: https://doi.org/10.1007/978-3-642-27340-7_4

Downloads

Published

2024-10-27

How to Cite

HASSAN, H., RIASAT, A., ZIA, T., ISHAQ, S., & ULLAH, A. (2024). CLASSIFICATION, PREVALENCE AND TREATMENT OF HEPACVIRIUS C. Journal of Physical, Biomedical and Biological Sciences, 2024(1), 33. https://doi.org/10.64013/jpbab.v2024i1.33